Precision Medicine Applied to Metastatic Colorectal Cancer Using Tumor-Derived Organoids and In-Vitro Sensitivity Testing: A Phase 2, Single-Center, Open-Label, and Non-Comparative Study

In this Phase II, single-center, open-label, non-comparative study, 90 patients with metastatic colorectal cancer following progression on or after standard therapy were enrolled. Patient-derived organoids and in vitro sensitivity testing were feasible in a cohort of metastatic colorectal cancer.